Argenx Bv

Argenx Bvba

Argen-x N.v.

Ludwig Institute for Cancer Research Limited

Universiteit Gent

Vib Vzw

Universitè Catholique De Louvain

Argenx Iip Bv

Michael Saunders

Sebastian Paul Van Der Woning

Johannes De Haard

Natalie De Jonge

Anna Hultberg

Els Festjens

Torsten Dreier

Paolo Michieli

Cristina Basilico

Johannes Joseph Wilhelmus De Haard

Hans De Haard

Christophe Frederic Jerome Blanchetot

Tine Skak-Nielsen

Birgitte Ursø

Malene Bertelsen

Pierre G Coulie

Jean-Christophe Renauld

Christophe Blanchetot

Sophie Lucas

Laure Dumoutier

Bart Lambrecht

Gitte De Boeck

Hamida Hammad

Julia Cuende Villasur

Savvas Savvides

Kenneth Verstraete

Jean-Michel Percier

Emma Persson

Paulo Michieli

Sebastian Van Der Woning

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Galectin-10 antibodies

The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Anti-IL-22R antibodies

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.

Anti c-Met antibodies

Antibody against a complex between human GARP and latent TGF-&#x3b2;

The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.

C-Met antibody combinations

Growing community of inventors

Brussels, Belgium

Michael Saunders